Last Updated: July 6, 2026

Claims for Patent: 8,354,509

✉ Email this page to a colleague

Summary for Patent: 8,354,509

Title:	Antibodies to human programmed death receptor PD-1
Abstract:	Antibodies which block the binding of human Programmed Death Receptor 1 (hPD-1) to its ligands (hPD-L1 or hPD-L2) and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune response through the PD-I pathway is also disclosed.
Inventor(s):	Carven Gregory John, van Eenennaam Hans, Dulos Gradus Johannes
Assignee:	MSD Oss B.V.
Application Number:	US12663950

Details for Patent 8,354,509

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	September 04, 2014	8,354,509	2028-06-13
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	Injection	125514	January 15, 2015	8,354,509	2028-06-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,354,509

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
South Africa	201000135	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2008156712	⤷ Start Trial
United States of America	9834605	⤷ Start Trial
United States of America	8952136	⤷ Start Trial
United States of America	8900587	⤷ Start Trial
United States of America	2021403560	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.